Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine versus remifentanil adjunct to ciprofol sedation in obese adults undergoing gastrointestinal endoscopy
ChiCTR2600135568Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine, remifentanil and ciprofol in obesity (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Incidence of hypoxemia. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
esketamineremifentanilciprofol
03
Conditions
obesity
Beyond the preview
Go deeper on ChiCTR2600135568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135568.